On January 21, 2020, Daniel O’Connor, President, Director & CEO of OncoSec Medical Incorporated sent a letter to shareholders. In the letter, Daniel O’Connor expressed his view that CGP/Sirtex Transaction is best option for the Company and would drive long-term value. Daniel O’Connor added that Institutional Shareholder Services Inc. and Glass, Lewis & Co. have recommended shareholders support CGP/Sirtex transaction. Daniel O’Connor also urged the Company shareholders to vote for the CGP/Sirtex transaction on the Company’s proxy card.